Impact of cytogenetic risk category on outcome in patients with secondary and with de novo MDS/tAML. (A) Probability of relapse. Low secondary indicates low risk in secondary group; low de novo, low risk in de novo group; int secondary, intermediate risk in secondary group; int de novo, intermediate risk in de novo group; high secondary, high risk in secondary group; and high de novo, high risk in de novo group. (B) Probability of relapse-free survival by cytogenetic risk for patients with secondary and de novo MDS/tAML. Cytogenetic risk groups according to IPSS criteria.